Skip to main content
. Author manuscript; available in PMC: 2022 Feb 12.
Published in final edited form as: Nature. 2021 Nov 3;599(7886):673–678. doi: 10.1038/s41586-021-04057-2

Extended Data Fig. 8 |. DDR1 antibody treatment inhibits spontaneous mammary tumour growth.

Extended Data Fig. 8 |

(a-b) Binding affinity of all four anti-ECD antibody clones for human (a) and mouse (b) DDR1. (c–d) Spontaneous MMTV-PyMT body weight of C57BL/6 hosts treated with control or #9 in the pre-tumour (from 11 weeks old, control: n = 7 mice, #9: n = 8 mice, c) and post-tumour groups (control n = 7 mice, #9 n = 8 mice, d). Data are presented as mean values +/− SEM. (e) Tumour incidence (percentage of tumour-bearing mammary glands per mouse, in MMTV-PyMT spontaneous mammary tumour model of C57BL/6 genetic background, treated in a “post-tumour” scheme with Ctrl (n = 7 mice) or anti-DDR1 #9 antibody (n = 8 mice). Data are presented as mean values + SEM. (f, g) Spontaneous MMTV-PyMT tumour growth in C57BL/6 hosts (accumulative tumour volume per mouse, f) and incidence percentage (per mouse, g) with pre-tumour treatment (control: n = 7 mice, #9: n = 8 mice). Data are presented as mean values +/− SEM. (h, i) Spontaneous MMTV-PyMT tumour growth (accumulative tumour volume per mouse) in FVB hosts treated with control or #9 before tumour growth (from 5 to 7 weeks old, h) and post-tumour groups (i). control: n = 7 mice, #9: n = 8 mice, n.s. not significant. Two-way ANOVA were used for all tests.